Views & Analysis | Perspectives on pharma industry issues

R&D

AMR and vaccines: Can universal coverage avert a post-antibi...

Antimicrobial resistance (AMR) is a growing global health crisis.

Patients

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

Changing Faces: Pharma and biotech, January 2026

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO changes at biotech firms.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Digital

Harnessing AI to make Medicare more efficient, fair, and pat...

As part of “WISeR” requirements, CMS selected tech vendors to implement enhanced technological models to scrutinise claims involving those on Medicare

Digital

pharmaphorum podcast Episode 226, Alfred Olivares, HTEC

Digital transformation as a third lever in the affordability...

Alfred Olivares, global managing partner, healthcare & medtech, at HTEC, discusses how AI and tech can help address the affordability challenge.

Market Access

Sustaining the mature product portfolio through strategic ou...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

Patients

Pills from bottle without label into palm of a man's hand

Meeting the growing demand for animal-free medicines

Pharmaceutical manufacturers have begun, albeit tentatively, to acknowledge and respond to evolving dietary sensibilities.

Patients

How to put out the waiting list fire – and make sure it neve...

NHS waiting lists are like fires that everyone is frantically trying to put out. But however much water we pour on it, the flames keep roaring.

AMR and vaccines: Can universal coverage avert a post-antibi...

From insight to impact: Why the patient voice will redefine ...

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Changing Faces: Pharma and biotech, January 2026

Four reasons pharma is sweeping the Super Bowl despite FDA f...

Harnessing AI to make Medicare more efficient, fair, and pat...

Digital transformation as a third lever in the affordability...

Sustaining the mature product portfolio through strategic ou...

Four reasons pharma is sweeping the Super Bowl despite FDA f...

On quality data for quality learnings, with Lisa Sims

From engagement metrics to meaningful experience: Why pharma...

How GenAI is cracking the toughest targets in drug discovery

Biotech leaders: ‘They're shoving this industry into the arm...

European biopharma at a crossroads

A cancer treatment modality that prioritises QoL, with Ben Z...

Improving breast cancer outcomes in sub-Saharan Africa

Engineering “smarter” cells, with Tim Lu

From insight to impact: Why the patient voice will redefine ...

Meeting the growing demand for animal-free medicines

How to put out the waiting list fire – and make sure it neve...

AMR and vaccines: Can universal coverage avert a post-antibi...

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Changing Faces: Pharma and biotech, January 2026

Takeda signs $1.7bn AI alliance with Iambic

How to meet your physicians where they are online

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks